Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELIMINATE-AF
2016-003069-25Phase 3Completed
- Sponsor
- Daiichi Sankyo
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in Atrial fibrillation (AFib) comparing Edoxaban with Warfarin / VKA (2 arms). Primary endpoint: Primary efficacy endpoint. Started Nov 2016; status: completed.
02
Drugs
edoxabanwarfarin
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on 2016-003069-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003069-25.